Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • CFI-402257Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)

Phase Distribution

Phase 2
1
25%
Phase 1
1
25%
Phase 1/2
2
50%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 1/2Combined phases
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 1/2

Trials by Phase

Phase 11 (25.0%)
Phase 1/22 (50.0%)
Phase 21 (25.0%)

Trials by Status

active_not_recruiting250%
completed125%
recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
completedphase_1

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

NCT02792465
recruitingphase_2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT05601440
active_not_recruitingphase_1_2

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

NCT03568422
active_not_recruitingphase_1_2

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

NCT05251714

Clinical Trials (4)

Showing 4 of 4 trials
NCT02792465Phase 1

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

Completed
NCT05601440Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
NCT03568422Phase 1/2

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Active Not Recruiting
NCT05251714Phase 1/2

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
4